Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT1A receptors expressed in HeLa cells
Authors:
- 20 November 2001
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 433 (1) , 55-62
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?Journal of Psychopharmacology, 2001
- The putative «silent» 5-HT1A receptor antagonist, WAY 100635, has inverse agonist properties at cloned human 5-HT1A receptorsEuropean Journal of Pharmacology, 2000
- Inverse agonism at G protein‐coupled receptors: (patho)physiological relevance and implications for drug discoveryBritish Journal of Pharmacology, 2000
- Mechanisms of Agonism and Inverse Agonism at Serotonin 5‐HT1A ReceptorsJournal of Neurochemistry, 2000
- Modulation of 5-HT1A receptor signalling by point-mutation of cysteine351 in the rat Gαo proteinNeuropharmacology, 1999
- 5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapineEuropean Journal of Pharmacology, 1997
- Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptorsBritish Journal of Pharmacology, 1997
- Prevention by (±)‐8‐hydroxy‐2‐(di‐npropylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidolBritish Journal of Pharmacology, 1996
- Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugsJournal of Pharmacy and Pharmacology, 1988
- A Controlled Clinical Trial of Tiaspirone in SchizophreniaInternational Clinical Psychopharmacology, 1987